OCUL Ocular Therapeutix Inc
Ocular Therapeutix Inc (OCUL) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $233.2K.
Where they traded
Last open-market purchase: February 20, 2026 , by LINDSTROM RICHARD L MD .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Notman Donald | Chief Operating Officer | Sell | 1,099 | $10.24 | $11.3K | 366,529 −0.3% of holding | |
| Dugel Pravin | See Remarks | Sell | 21,649 | $10.77 | $233.2K | 2,525,429 −0.8% of holding | |
| Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,296 | $10.78 | $35.5K | 318,326 −1% of holding | |
| Kaiser Peter | Chief Development Officer | Sell | 3,035 | $10.77 | $32.7K | 264,378 −1.1% of holding | |
| Nayak Sanjay | Chief Strategy Officer | Sell | 1,897 | $10.78 | $20.4K | 326,898 −0.6% of holding | |
| Waheed Nadia | Chief Medical Officer | Sell | 14,828 | $8.27 | $122.6K | 300,079 −4.7% of holding | |
| Dugel Pravin | See Remarks | Sell | 21,156 | $8.20 | $173.5K | 2,597,170 −0.8% of holding | |
| Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,018 | $8.20 | $24.7K | 320,350 −0.9% of holding | |
| Kaiser Peter | Chief Development Officer | Sell | 2,967 | $8.20 | $24.3K | 266,141 −1.1% of holding | |
| Nayak Sanjay | Chief Strategy Officer | Sell | 1,858 | $8.20 | $15.2K | 328,795 −0.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.